Evidence map›Paper›PMID 34802503›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2021

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.

E Mohr-Holland, D Hacking, J Daniels, V Scott, V Mudaly, J Furin, C Pfaff, A Reuter

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

E Mohr-HollandMédecins Sans Frontières (MSF), Khayelitsha, South Africa, MSF Southern Africa Medical Unit, Cape Town, South Africa.
D HackingMédecins Sans Frontières (MSF), Khayelitsha, South Africa.
J DanielsMédecins Sans Frontières (MSF), Khayelitsha, South Africa.
V ScottCity of Cape Town Department of Health, Eastern Area, Cape Town, South Africa.
V MudalyProvincial Government of the Western Cape, Cape Town, South Africa.
J FurinHarvard Medical School, Boston, MA, USA.
C PfaffMédecins Sans Frontières (MSF), Khayelitsha, South Africa.
A ReuterMédecins Sans Frontières (MSF), Khayelitsha, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibiotics, AntitubercularCOVID-19Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansRifampinSARS-CoV-2Antibiotics, AntitubercularRifampin

Identifiers

PMID34802503
PMCPMC8412107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.